Skip to main
PFE
PFE logo

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 31 analyst ratings
Hold
Strong Buy 23%
Buy 13%
Hold 61%
Sell 3%
Strong Sell 0%

Bulls say

Pfizer demonstrated strong financial performance in 4Q 2024, surpassing both internal and consensus estimates due to increased sales of key products such as Comirnaty, Paxlovid, Eliquis, and Ibrance, despite lower-than-expected revenues from Abrysvo. The company’s management has maintained its FY 2025 guidance, focusing on stabilizing COVID-19 revenues while pursuing cost realignment and leveraging pipeline opportunities to enhance future growth. Additionally, there is optimism regarding clinical updates from Pfizer's obesity and oncology pipelines, expected in 2025, which may further solidify the company's market position and drive stock performance.

Bears say

Pfizer's outlook is negatively affected by several factors, including disappointing commercial performance of key products such as Padcev and Abrysvo, alongside potential regulatory setbacks for pipeline drugs. The company has made model adjustments that reflect a decrease in near-term sales projections for specific drugs while attempting to realign costs, indicating challenges in growth stability. Additionally, ongoing concerns over US drug pricing reforms may dampen investor interest in Pfizer amidst its reliance on higher-priced medicines, suggesting a potentially diminishing market appeal.

Pfizer (PFE) has been analyzed by 31 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 13% recommend Buy, 61% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 31 analysts, Pfizer (PFE) has a Hold consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.